Get our latest issue now

available for iOS, Android & web

latest issue

Teva gets FDA OK for generic Combivir

Daily News | May 27, 2011

Kevin Grogan

Teva gets FDA OK for generic Combivir

Teva Pharmaceutical Industries has been granted the first approval to market a generic version of the HIV drug Combivir.

The branded version of Combivir (zidovudine and lamivudine) is currently marketed by ViiV Healthcare, GlaxoSmithKline and Pfizer's HIV joint venture. It has annual US sales of around $315 million, according to IMS data.

Now the US Food and Drug Administration has given the green light to Teva's copycat version. Shipment is expected to commence during the fourth quarter of 2011, as per the terms of a settlement between Teva, GSK and ViiV.

As the first company to file an Abbreviated New Drug Application for generic Combivir, the Israeli drugmaker is eligible for a 180-day period of marketing exclusivity.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!


Most read articles

Latest Jobs